Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
Previous Symbol
CUSIP87837710
Phone612-379-8854
Debt
Debt-to-Equity Ratio0.49
Current Ratio4.59
Quick Ratio3.50
Price-To-Earnings
Trailing P/E Ratio38.38
Forward P/E Ratio41.22
P/E Growth2.75
Sales & Book Value
Annual Sales$642.99 million
Price / Sales9.18
Cash Flow$5.8356 per share
Price / Cash Flow26.77
Book Value$28.72 per share
Price / Book5.44
Profitability
EPS (Most Recent Fiscal Year)$4.07
Net Income$126.15 million
Net Margins19.19%
Return on Equity14.09%
Return on Assets9.01%
Miscellaneous
Employees2,000
Outstanding Shares37,770,000
Market Cap$5.90 billion
OptionableOptionable
BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions
What is BIO-TECHNE's stock symbol?
BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."
How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?
BIO-TECHNE declared a quarterly dividend on Tuesday, October 30th. Investors of record on Friday, November 9th will be given a dividend of $0.32 per share on Friday, November 23rd. This represents a $1.28 annualized dividend and a yield of 0.82%. The ex-dividend date is Thursday, November 8th. View BIO-TECHNE's Dividend History.
How were BIO-TECHNE's earnings last quarter?
BIO-TECHNE Corp (NASDAQ:TECH) announced its quarterly earnings data on Tuesday, October, 30th. The biotechnology company reported $0.98 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.95 by $0.03. The biotechnology company earned $163 million during the quarter, compared to the consensus estimate of $162.34 million. BIO-TECHNE had a net margin of 19.19% and a return on equity of 14.09%. BIO-TECHNE's quarterly revenue was up 12.7% on a year-over-year basis. During the same quarter last year, the company earned $0.90 EPS. View BIO-TECHNE's Earnings History.
When is BIO-TECHNE's next earnings date?
What price target have analysts set for TECH?
7 brokerages have issued 1-year target prices for BIO-TECHNE's stock. Their predictions range from $154.00 to $230.00. On average, they anticipate BIO-TECHNE's stock price to reach $185.7143 in the next twelve months. This suggests a possible upside of 18.9% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.
What is the consensus analysts' recommendation for BIO-TECHNE?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.
Has BIO-TECHNE been receiving favorable news coverage?
News articles about TECH stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIO-TECHNE earned a news impact score of 0.8 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Are investors shorting BIO-TECHNE?
BIO-TECHNE saw a drop in short interest in October. As of October 31st, there was short interest totalling 479,048 shares, a drop of 28.3% from the October 15th total of 668,565 shares. Based on an average daily volume of 354,034 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.3% of the shares of the stock are short sold. View BIO-TECHNE's Current Options Chain.
Who are some of BIO-TECHNE's key competitors?
Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Denali Therapeutics (DNLI) and Atara Biotherapeutics (ATRA).
Who are BIO-TECHNE's key executives?
BIO-TECHNE's management team includes the folowing people:
- Mr. Charles R. Kummeth, CEO, Pres & Director (Age 58)
- Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 47)
- Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 60)
- Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 57)
- Mr. Gerry Andros, VP of Sales and Marketing
Who are BIO-TECHNE's major shareholders?
BIO-TECHNE's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.99%), Vanguard Group Inc. (8.90%), Atlanta Capital Management Co. L L C (4.24%), Neuberger Berman Group LLC (4.05%), Bamco Inc. NY (4.00%) and Jackson Square Partners LLC (2.13%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, Charles R Kummeth, John L Higgins, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.
Which institutional investors are selling BIO-TECHNE stock?
TECH stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Atlanta Capital Management Co. L L C, Royce & Associates LP, Epoch Investment Partners Inc., Prudential Financial Inc., Schroder Investment Management Group, Neuberger Berman Group LLC and Allianz Asset Management GmbH. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Charles R Kummeth and John L Higgins. View Insider Buying and Selling for BIO-TECHNE.
Which institutional investors are buying BIO-TECHNE stock?
TECH stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Kornitzer Capital Management Inc. KS, AQR Capital Management LLC, Rehmann Capital Advisory Group, Massachusetts Financial Services Co. MA, Vanguard Group Inc., Assenagon Asset Management S.A. and Conestoga Capital Advisors LLC. View Insider Buying and Selling for BIO-TECHNE.
How do I buy shares of BIO-TECHNE?
Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIO-TECHNE's stock price today?
One share of TECH stock can currently be purchased for approximately $156.22.
How big of a company is BIO-TECHNE?
BIO-TECHNE has a market capitalization of $5.90 billion and generates $642.99 million in revenue each year. The biotechnology company earns $126.15 million in net income (profit) each year or $4.07 on an earnings per share basis. BIO-TECHNE employs 2,000 workers across the globe.
What is BIO-TECHNE's official website?
How can I contact BIO-TECHNE?
BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]
MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
